BACKGROUND/AIMS: Neutrophil elastase is a proteinase which exists in granulocytes and plays an important role in the pathogenesis of inflammatory disorders. In inflammatory bowel disease there is a leukocyte infiltration of the bowel mucosa. The purpose of this study was to examine whether plasma elastase represents a reliable laboratory marker for establishing the activity of chronic inflammatory bowel disease. METHODOLOGY: We measured plasma elastase concentrations in 61 patients suffering from either Crohn's disease or ulcerative colitis and compared these data with other clinical and laboratory findings and with elastase concentrations in 40 healthy controls. The sensitivity and specificity of the elastase values in chronic IBD were calculated with the use of concomitant measurements of CRP and ESR. RESULTS: Plasma levels were found to be significantly higher in patients (49 micrograms/l) compared with healthy controls (23 micrograms/l). Patients with active disease had higher plasma levels than patients in remission. In general, the sensitivity of elastase to detect active inflammatory bowel disease was about 60%; the specificity was 65%. For patients in remission, the sensitivity was higher than 80%. However, there was a wide range of overlapping values between chronic inactive patients and those with moderately active disease. CONCLUSIONS: We conclude that plasma elastase is a useful independent marker of disease activity in inflammatory bowel disease. Especially for identifying patients in remission, the measurements of elastase seem to be more suitable than other parameters of inflammation, like CRP or ESR.
BACKGROUND/AIMS: Neutrophil elastase is a proteinase which exists in granulocytes and plays an important role in the pathogenesis of inflammatory disorders. In inflammatory bowel disease there is a leukocyte infiltration of the bowel mucosa. The purpose of this study was to examine whether plasma elastase represents a reliable laboratory marker for establishing the activity of chronic inflammatory bowel disease. METHODOLOGY: We measured plasma elastase concentrations in 61 patients suffering from either Crohn's disease or ulcerative colitis and compared these data with other clinical and laboratory findings and with elastase concentrations in 40 healthy controls. The sensitivity and specificity of the elastase values in chronic IBD were calculated with the use of concomitant measurements of CRP and ESR. RESULTS: Plasma levels were found to be significantly higher in patients (49 micrograms/l) compared with healthy controls (23 micrograms/l). Patients with active disease had higher plasma levels than patients in remission. In general, the sensitivity of elastase to detect active inflammatory bowel disease was about 60%; the specificity was 65%. For patients in remission, the sensitivity was higher than 80%. However, there was a wide range of overlapping values between chronic inactive patients and those with moderately active disease. CONCLUSIONS: We conclude that plasma elastase is a useful independent marker of disease activity in inflammatory bowel disease. Especially for identifying patients in remission, the measurements of elastase seem to be more suitable than other parameters of inflammation, like CRP or ESR.
Authors: Kelley Mk Haarberg; Meghan J Wymore Brand; Anne-Marie C Overstreet; Catherine C Hauck; Patricia A Murphy; Jesse M Hostetter; Amanda E Ramer-Tait; Michael J Wannemuehler Journal: World J Gastrointest Pharmacol Ther Date: 2015-11-06
Authors: Marta S Alexdottir; Arno R Bourgonje; Morten A Karsdal; Martin Pehrsson; Roberta Loveikyte; Hendrik M van Dullemen; Marijn C Visschedijk; Eleonora A M Festen; Rinse K Weersma; Klaas Nico Faber; Gerard Dijkstra; Joachim H Mortensen Journal: Int J Mol Sci Date: 2022-07-23 Impact factor: 6.208
Authors: Joachim Høg Mortensen; Dovile Sinkeviciute; Tina Manon-Jensen; Viktor Domislović; Kathryn McCall; Christian S Thudium; Marko Brinar; Patrik Önnerfjord; Carl S Goodyear; Željko Krznarić; Morten Asser Karsdal; Anne-Christine Bay-Jensen Journal: J Crohns Colitis Date: 2022-09-08 Impact factor: 10.020
Authors: Angie L Schroder; Belal Chami; Yuyang Liu; Chloe M Doyle; Mary El Kazzi; Golo Ahlenstiel; Gulfam Ahmad; Nimalan Pathma-Nathan; Geoff Collins; James Toh; Andrew Harman; Scott Byrne; Grahame Ctercteko; Paul K Witting Journal: Inflamm Bowel Dis Date: 2022-03-30 Impact factor: 7.290
Authors: Joachim Høg Mortensen; Tina Manon-Jensen; Michael Dam Jensen; Per Hägglund; Lone Gabriels Klinge; Jens Kjeldsen; Aleksander Krag; Morten Asser Karsdal; Anne-Christine Bay-Jensen Journal: PLoS One Date: 2017-10-13 Impact factor: 3.240
Authors: Liang Zhang; Craig D Wallace; Jamie E Erickson; Christine M Nelson; Stephanie M Gaudette; Calvin S Pohl; Samuel D Karsen; Gricelda H Simler; Ruoqi Peng; Christopher A Stedman; F Stephen Laroux; Marc A Wurbel; Rajesh V Kamath; Bradford L McRae; Annette J Schwartz Sterman; Soumya Mitra Journal: Sci Rep Date: 2020-03-13 Impact factor: 4.379